Related Experiment Video
Updated: Dec 8, 2025
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
NF-κB Inhibition Suppresses Experimental Melanoma Lung Metastasis
Tomoko Stansel1, Samuel A Wickline1, Hua Pan1
1The USF Health Heart Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Background:
Although novel therapeutic regimens for melanoma continue to emerge, the best current clinical response rate is still less than 60%. Moreover, antimelanoma treatments contribute to toxicities in other vital organs. In this study, we elucidate the therapeutic advantages of siRNA targeting melanoma NF-κB canonical signaling pathway with a peptide-based gene delivery nanoplex system.
Methods And Results:
In vitro treatment of melanoma B16-F10 cells was used to demonstrate delivery and efficacy of anti-NF-kB siRNA to cell cytoplasm with a 55 mn peptide-based gene delivery system. NF-κB (p65) knockdown was validated both at mRNA and protein levels by using RT2-PCR, western blot, and immunofluorescence cellular staining. Canonical p65 mRNA was reduced by 82% and p65 protein was reduced by 48%, which differed significantly from levels in control groups. In vivo treatment of a melanoma lung metastasis mouse model with 3-serial i.v. injections of p5RHH-p65 siRNA nanoparticles retarded growth of lung metastasis within one week by 76% (p=0.003) as compared to saline control treatments.
Conclusion:
Inhibition of melanoma NF-κB (p65) with systemically-delivered siRNA effectively impedes the growth and progression of experimental melanoma lung metastasis.
Insights
This study demonstrates that peptide-nanoparticle delivery of small interfering RNA (siRNA) targeting the NF-κB pathway significantly inhibits melanoma growth and metastasis in mice, offering a promising new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Nanotechnology
Background:
- Current melanoma treatments have response rates below 60% and cause significant toxicities.
- There is a need for more effective and targeted melanoma therapies.
Purpose of the Study:
- To investigate the therapeutic potential of siRNA targeting the NF-κB canonical signaling pathway in melanoma.
- To evaluate a peptide-based gene delivery nanoplex system for melanoma treatment.
Main Methods:
- In vitro studies using B16-F10 melanoma cells to confirm siRNA delivery and knockdown of NF-κB (p65) at mRNA and protein levels.
- In vivo experiments involving a melanoma lung metastasis mouse model treated with p5RHH-p65 siRNA nanoparticles via intravenous injections.
Main Results:
- NF-κB (p65) mRNA and protein levels were significantly reduced (82% and 48%, respectively) in treated cells.
- Systemic administration of siRNA nanoparticles resulted in a 76% retardation of lung metastasis growth within one week in mice.
Conclusions:
- Systemic delivery of siRNA targeting melanoma NF-κB (p65) effectively inhibits experimental melanoma lung metastasis.
- Peptide-based nanoplex systems show promise for targeted gene therapy in melanoma.
More Related Videos
07:41A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
